Quaker BioVentures

Quaker BioVentures is a venture capital firm investing in life science companies, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. The firm leads investments across the spectrum of the life science industry, from early-stage start-ups to public companies. Founded in 2003, Quaker BioVentures manages over $700 million in committed capital, with its second fund, Quaker BioVentures II, being a $420 million fund formed in 2007.

The firm's investment strategy encompasses a wide range of stages, including seed, early stage, late stage, growth, pre-IPO, buyout, turnaround, and distressed investments. Geographically, Quaker BioVentures focuses on the United States and the United Kingdom. The industries of interest include biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services.

Quaker BioVentures has a track record of investing in companies such as Kaarta, Neuronetics, PreCision Dermatology, RainDance Technologies, Intact Vascular, Tarsa Therapeutics, NovaSom, Neuronetics, RainDance Technologies, TetraLogic Pharmaceuticals, and others. The firm's portfolio reflects its commitment to supporting innovative companies across various sectors within the life sciences industry.